Multidrug resistance protein expression in chronic myeloid leukemia: Associations and significance

Francis J. Giles, Hagop M. Kantarjian, Jorge Cortes, Deborah A. Thomas, Moshe Talpaz, Taghi Manshouri, Maher Albitar

Research output: Contribution to journalArticle

Abstract

BACKGROUND. Overexpression of the multidrug resistance gene (MDR1) product, the MDR1 protein (MDR1), has been associated with poor prognosis in several hematologic malignancies. The significance of MDR1 levels in patients with chronic myeloid leukemia (CML) has not been established. METHODS. The authors investigated MDR1 levels and their association with patient and tumor characteristics, responsiveness to therapy, and long term prognosis in 198 CML patients. These included 127 patients in early chronic phase (ECP) CML, 31 patients in late chronic phase (LCP) CML, and 40 patients in accelerated or blastic phase CML. MDR1 expression was analyzed by Western blot analysis and quantitative solid-phase plate radioimmunoassay. MDR1 levels were measured on cell lysates obtained from the bone marrow mononuclear cell fraction. Expression was compared in relation to the median derived from 36 normal control samples. RESULTS. Among patients with CML, high levels of MDR1 were found in 73 of 127 ECP (57%), 20 of 31 LCP (65%), 8 of 27 in accelerated phase (30%), and 8 of 13 in blastic phase (62%) (P value not significant). Furthermore, among the 127 ECP CML patients, high MDR1 levels were associated with age ≥50 years (69% vs. 51%; P < 0.05), thrombocytosis ≥700 x 109/L (84% vs. 53%; P < 0.01), and leukocyte counts ≤50 x 109/L (70% vs. 46%; P<0.01). Response to interferon α (IFN-α) was independent of MDR1 expression; major cytogenetic responses were recorded in 28 of 73 patients with high MDR1 levels and in 16 of 54 patients with low MDR1 levels (38% vs. 30%; P value not significant). No difference in survival based on MDR1 level was observed. A small subset of 17 patients with low MDR1 levels (<1 times normal) had a trend toward worse survival (median, 30 months vs. 73 months; 5-year survival rates of 34% vs. 65%; P = 0.03). CONCLUSIONS. The results of the current study demonstrate that MDR1 overexpression was not associated with disease progression, responsiveness to IFN-α therapy, or survival in patients with ECP CML.

Original languageEnglish (US)
Pages (from-to)805-813
Number of pages9
JournalCancer
Volume86
Issue number5
DOIs
StatePublished - Sep 1 1999
Externally publishedYes

Fingerprint

P-Glycoproteins
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Chronic Phase
Interferons
Survival
MDR Genes
Thrombocytosis
P-Glycoprotein
Hematologic Neoplasms
Leukocyte Count
Cytogenetics
Bone Marrow Cells
Radioimmunoassay
Disease Progression

Keywords

  • Chronic myeloid leukemia
  • Interferon-α, chronic phase
  • Multidrug resistance protein

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Multidrug resistance protein expression in chronic myeloid leukemia : Associations and significance. / Giles, Francis J.; Kantarjian, Hagop M.; Cortes, Jorge; Thomas, Deborah A.; Talpaz, Moshe; Manshouri, Taghi; Albitar, Maher.

In: Cancer, Vol. 86, No. 5, 01.09.1999, p. 805-813.

Research output: Contribution to journalArticle

Giles, Francis J. ; Kantarjian, Hagop M. ; Cortes, Jorge ; Thomas, Deborah A. ; Talpaz, Moshe ; Manshouri, Taghi ; Albitar, Maher. / Multidrug resistance protein expression in chronic myeloid leukemia : Associations and significance. In: Cancer. 1999 ; Vol. 86, No. 5. pp. 805-813.
@article{9a1b4abb254c474cadb0ca85a6c49db9,
title = "Multidrug resistance protein expression in chronic myeloid leukemia: Associations and significance",
abstract = "BACKGROUND. Overexpression of the multidrug resistance gene (MDR1) product, the MDR1 protein (MDR1), has been associated with poor prognosis in several hematologic malignancies. The significance of MDR1 levels in patients with chronic myeloid leukemia (CML) has not been established. METHODS. The authors investigated MDR1 levels and their association with patient and tumor characteristics, responsiveness to therapy, and long term prognosis in 198 CML patients. These included 127 patients in early chronic phase (ECP) CML, 31 patients in late chronic phase (LCP) CML, and 40 patients in accelerated or blastic phase CML. MDR1 expression was analyzed by Western blot analysis and quantitative solid-phase plate radioimmunoassay. MDR1 levels were measured on cell lysates obtained from the bone marrow mononuclear cell fraction. Expression was compared in relation to the median derived from 36 normal control samples. RESULTS. Among patients with CML, high levels of MDR1 were found in 73 of 127 ECP (57{\%}), 20 of 31 LCP (65{\%}), 8 of 27 in accelerated phase (30{\%}), and 8 of 13 in blastic phase (62{\%}) (P value not significant). Furthermore, among the 127 ECP CML patients, high MDR1 levels were associated with age ≥50 years (69{\%} vs. 51{\%}; P < 0.05), thrombocytosis ≥700 x 109/L (84{\%} vs. 53{\%}; P < 0.01), and leukocyte counts ≤50 x 109/L (70{\%} vs. 46{\%}; P<0.01). Response to interferon α (IFN-α) was independent of MDR1 expression; major cytogenetic responses were recorded in 28 of 73 patients with high MDR1 levels and in 16 of 54 patients with low MDR1 levels (38{\%} vs. 30{\%}; P value not significant). No difference in survival based on MDR1 level was observed. A small subset of 17 patients with low MDR1 levels (<1 times normal) had a trend toward worse survival (median, 30 months vs. 73 months; 5-year survival rates of 34{\%} vs. 65{\%}; P = 0.03). CONCLUSIONS. The results of the current study demonstrate that MDR1 overexpression was not associated with disease progression, responsiveness to IFN-α therapy, or survival in patients with ECP CML.",
keywords = "Chronic myeloid leukemia, Interferon-α, chronic phase, Multidrug resistance protein",
author = "Giles, {Francis J.} and Kantarjian, {Hagop M.} and Jorge Cortes and Thomas, {Deborah A.} and Moshe Talpaz and Taghi Manshouri and Maher Albitar",
year = "1999",
month = "9",
day = "1",
doi = "10.1002/(SICI)1097-0142(19990901)86:5<805::AID-CNCR16>3.0.CO;2-E",
language = "English (US)",
volume = "86",
pages = "805--813",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Multidrug resistance protein expression in chronic myeloid leukemia

T2 - Associations and significance

AU - Giles, Francis J.

AU - Kantarjian, Hagop M.

AU - Cortes, Jorge

AU - Thomas, Deborah A.

AU - Talpaz, Moshe

AU - Manshouri, Taghi

AU - Albitar, Maher

PY - 1999/9/1

Y1 - 1999/9/1

N2 - BACKGROUND. Overexpression of the multidrug resistance gene (MDR1) product, the MDR1 protein (MDR1), has been associated with poor prognosis in several hematologic malignancies. The significance of MDR1 levels in patients with chronic myeloid leukemia (CML) has not been established. METHODS. The authors investigated MDR1 levels and their association with patient and tumor characteristics, responsiveness to therapy, and long term prognosis in 198 CML patients. These included 127 patients in early chronic phase (ECP) CML, 31 patients in late chronic phase (LCP) CML, and 40 patients in accelerated or blastic phase CML. MDR1 expression was analyzed by Western blot analysis and quantitative solid-phase plate radioimmunoassay. MDR1 levels were measured on cell lysates obtained from the bone marrow mononuclear cell fraction. Expression was compared in relation to the median derived from 36 normal control samples. RESULTS. Among patients with CML, high levels of MDR1 were found in 73 of 127 ECP (57%), 20 of 31 LCP (65%), 8 of 27 in accelerated phase (30%), and 8 of 13 in blastic phase (62%) (P value not significant). Furthermore, among the 127 ECP CML patients, high MDR1 levels were associated with age ≥50 years (69% vs. 51%; P < 0.05), thrombocytosis ≥700 x 109/L (84% vs. 53%; P < 0.01), and leukocyte counts ≤50 x 109/L (70% vs. 46%; P<0.01). Response to interferon α (IFN-α) was independent of MDR1 expression; major cytogenetic responses were recorded in 28 of 73 patients with high MDR1 levels and in 16 of 54 patients with low MDR1 levels (38% vs. 30%; P value not significant). No difference in survival based on MDR1 level was observed. A small subset of 17 patients with low MDR1 levels (<1 times normal) had a trend toward worse survival (median, 30 months vs. 73 months; 5-year survival rates of 34% vs. 65%; P = 0.03). CONCLUSIONS. The results of the current study demonstrate that MDR1 overexpression was not associated with disease progression, responsiveness to IFN-α therapy, or survival in patients with ECP CML.

AB - BACKGROUND. Overexpression of the multidrug resistance gene (MDR1) product, the MDR1 protein (MDR1), has been associated with poor prognosis in several hematologic malignancies. The significance of MDR1 levels in patients with chronic myeloid leukemia (CML) has not been established. METHODS. The authors investigated MDR1 levels and their association with patient and tumor characteristics, responsiveness to therapy, and long term prognosis in 198 CML patients. These included 127 patients in early chronic phase (ECP) CML, 31 patients in late chronic phase (LCP) CML, and 40 patients in accelerated or blastic phase CML. MDR1 expression was analyzed by Western blot analysis and quantitative solid-phase plate radioimmunoassay. MDR1 levels were measured on cell lysates obtained from the bone marrow mononuclear cell fraction. Expression was compared in relation to the median derived from 36 normal control samples. RESULTS. Among patients with CML, high levels of MDR1 were found in 73 of 127 ECP (57%), 20 of 31 LCP (65%), 8 of 27 in accelerated phase (30%), and 8 of 13 in blastic phase (62%) (P value not significant). Furthermore, among the 127 ECP CML patients, high MDR1 levels were associated with age ≥50 years (69% vs. 51%; P < 0.05), thrombocytosis ≥700 x 109/L (84% vs. 53%; P < 0.01), and leukocyte counts ≤50 x 109/L (70% vs. 46%; P<0.01). Response to interferon α (IFN-α) was independent of MDR1 expression; major cytogenetic responses were recorded in 28 of 73 patients with high MDR1 levels and in 16 of 54 patients with low MDR1 levels (38% vs. 30%; P value not significant). No difference in survival based on MDR1 level was observed. A small subset of 17 patients with low MDR1 levels (<1 times normal) had a trend toward worse survival (median, 30 months vs. 73 months; 5-year survival rates of 34% vs. 65%; P = 0.03). CONCLUSIONS. The results of the current study demonstrate that MDR1 overexpression was not associated with disease progression, responsiveness to IFN-α therapy, or survival in patients with ECP CML.

KW - Chronic myeloid leukemia

KW - Interferon-α, chronic phase

KW - Multidrug resistance protein

UR - http://www.scopus.com/inward/record.url?scp=0033197989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033197989&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19990901)86:5<805::AID-CNCR16>3.0.CO;2-E

DO - 10.1002/(SICI)1097-0142(19990901)86:5<805::AID-CNCR16>3.0.CO;2-E

M3 - Article

C2 - 10463979

AN - SCOPUS:0033197989

VL - 86

SP - 805

EP - 813

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -